The abstract is read at the publisher; the summary is JClub's.
Early pregnancy exposure to anti-CGRP monoclonal antibodies in a cohort of 7579 singleton pregnancies is linked to higher spontaneous abortion risk (aHR 1.42; 95% CI 1.12–1.80).
- Why it matters: Migraine treatment during pregnancy is constrained by safety concerns, yet CGRP is important for placental development, leaving uncertainty about whether anti-CGRP mAbs increase early pregnancy loss.
- What they did: In the AM-PREGNANT retrospective cohort (2018–2021), 7119 insured people with pregestational migraine were followed to 20 weeks or until spontaneous abortion; exposures were modeled as time-varying anti-CGRP mAbs (erenumab, fremanezumab, galcanezumab, eptinezumab) or propranolol.
- The result: Anti-CGRP mAb exposure showed an increased risk of spontaneous abortion versus no exposure, with bias-adjusted estimates remaining similar (HR 1.33; 95% SI 1.23–1.45), while propranolol was not associated (aHR 1.02; 95% CI 0.71–1.47).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.